Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of HSP70 family proteins as targets of anti-melanosome monoclonal antibodies by immunoprecipitation and LC–MS/MS

ABSTRACT: This dataset contains proteomic analyses performed to identify the molecular targets of three anti-melanosome monoclonal antibodies (mAbs): Mel321-31, Mel322-34, and Mel321-35. These antibodies were generated following immunization of mice with purified melanosomes and were shown to bind melanosomes by ELISA and flow cytometry. To determine their protein targets, melanosomal lysates were subjected to immunoprecipitation using each mAb. An isotype control antibody (mGO.53), which does not bind melanosomes, was used to define background binding. Each antibody condition was analyzed in four independent replicates (n=4), resulting in a total of 16 samples (3 experimental antibodies + 1 isotype control). Enriched proteins were identified by label-free quantitative LC–MS/MS and statistically compared to the isotype control group. The analysis revealed significant enrichment of HSP70 family members (HspA1A, HspA1L, HspA5, and HspA8), identifying HSP70 proteins as the primary targets of the anti-melanosome mAbs.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Skin

DISEASE(S): Melanoma

SUBMITTER: Noam Ben Shalom

LAB HEAD: Natalia T

PROVIDER: PXD074667 | Pride | 2026-02-23

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	HFS.zip	Other
	Seq87658_HF.raw	Raw
	Seq87659_HF.raw	Raw
	Seq87660_HF.raw	Raw
	Seq87661_HF.raw	Raw

Items per page:

1 - 5 of 20

Similar Datasets

Infection of RAW 264.7 cells by Murine Leukemia Virus-derived retroviral pseudotype expressing the envelope glycoprotein of EBOV is enhanced by immune serum and monoclonal antibodies

Project description:It has been shown that antibodies can enhance Ebola virus (EBOV) infection at sub-neutralizing concentrations. The effect of antibodies on the infection of murine cell line (RAW 264.7) with MLV-EBOV, a murine leukemia virus pseudotype expressing surface glycoprotein (GP) of EBOV and green fluorescent protein (GFP) has been studied. Moreover, regions of EBOV GP targeted by antibodies enhancing the infection have been investigated. Serum and monoclonal antibodies (mAbs) were obtained from mice inoculated with MLV-EBOV. Plasma from patients and humanized anti-EBOV GP mAbs were obtained. The proportion of GFP-positive cells was determined by immunocytofluorometry. Trypsin-digested EBOV GP was incubated in affinity columns prepared with mAbs. Eluted peptides were analyzed by high-resolution mass spectrometry. The infection of cells with MLV-EBOV was enhanced by immune mouse serum, human plasma and mAbs. The infection was the result of interactions between MLV-EBOV /antibody complexes and FcγRs. Regions of EBOV GP, located in GP1 core, furin cleavage site, N-terminal part of GP2, and HR1 and HR2 domains are target of antibodies able to enhance the infection. In conclusion, the RAW 264.7 cell line associated with MLV-EBOV can be used to study the enhancing activity of murine and human antibodies and may help to select antibodies or vaccine formulations that do not lead to enhancement of EBOV infection.

2026-01-26 | PXD066513 | Pride

ESK1 and MAGE-A4 TCR-like antibody immunoprecipitation in human liver tissue

Project description:We chose to perform a head-to-head immune-enrichment from primary liver tissue resections using both, MAGE-A4 and ESK1 TCR-like antibodies. Since both target antigens MAGE-A4 and WT-1 are not expressed in hepatocytes (Human Protein Atlas, www.proteinatlas.org), the ESK1 enrichment could serve as isotype control for the MAGE-A4 antibody, and vice versa.

2024-03-30 | PXD048294 | Pride

The Bartonella autotransporter CFA is a protective antigen and hypervariable target of neutralizing antibodies blocking erythrocyte infection

Project description:Antibodies are key to the clearance of Bartonella bacteremia, but the mechanisms and targets of protective antibodies are unknown and bacterial evasion strategies remain elusive. We studied experimental Bartonella taylorii infection of mice, its natural host, and investigated protective immune responses. Clearance of bacteremia depended on specific antibodies that interfere with bacterial attachment to erythrocytes. Accordingly, antibodies were effective in the absence of complement and Fc-receptors. Moreover, they formed independently of B-cell hypermutation and isotype class switch. The cloning of neutralizing monoclonal antibodies (mAbs) led to the identification of the bacterial autotransporter CFA as a protective antibody target, and vaccination against CFA protected against Bartonella bacteremia. MAb binding mapped to a region of CFA that is hypervariable in both human- and mouse-pathogenic Bartonella strains, suggesting mutational antibody evasion. These insights further our understanding of Bartonella immunity and immune evasion and elucidate mechanisms driving high Bartonella prevalence in the wild.

2022-08-12 | PXD028783 | Pride

1D LC-MS/MS proteomic profiling of MCF10A, HeLa, Hep G2, and HEK293 cells using peptide-based immunoaffinity enrichment and 105 commercially available monoclonal antibodies to proteins associated with the DNA damage response (DDR) network

Project description:Immunoaffinity enrichment of peptides coupled to multiple reaction monitoring-mass spectrometry (immuno-MRM) enables highly specific, sensitive, and precise quantification of peptides and post-translational modifications. Major obstacles to developing a large number of immuno-MRM assays are the poor availability of monoclonal antibodies (mAbs) validated for immunoaffinity enrichment of peptides and the cost and lead time of developing the antibodies de novo. Although many thousands of mAbs are commercially offered, few have been tested for application to immunoaffinity enrichment of peptides. In this study we tested the success rate of using commercially available mAbs for peptide immuno-MRM assays. We selected 105 commercial mAbs (76 targeting non-modified “pan” epitopes, 29 targeting phosphorylation) to proteins associated with the DNA damage response network. We found that 8 of the 76 pan (11%) and 5 of the 29 phospho-specific mAbs (17%) captured tryptic peptides (detected by LC-MS/MS) of their protein targets from human cell lysates. Seven of these mAbs were successfully used to configure and analytically characterize immuno-MRM assays. By applying selection criteria, the results indicate a success rate up to 24% is possible, establishing the feasibility of screening a large number of catalog antibodies to provide readily-available assay reagents.

2016-04-13 | PXD003370 | Pride

De Novo Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Top-Down and Bottom-Up Mass Spectrometry

Project description:Antibodies are specialized proteins produced by the adaptive immune system to identify and neutralize harmful antigens. Antibody-based diagnostics and therapeutics have advanced rapidly, with recombinant antibodies derived from monoclonal antibodies (mAbs) becoming the preferred standard due to their high reproducibility and effectiveness. However, mAbs are limited to binding a single antigen epitope. Polyclonal antibodies (pAbs), on the other hand, are produced by multiple B cells and can target multiple epitopes, making them more robust against antigen variations. Despite their advantages, pAbs are notoriously challenging to sequence due to their high complexity. Current de novo sequencing methods based on mass spectrometry have shown limitations when applied to pAb mixtures, often requiring germline databases or yielding incomplete or inaccurate sequences. Here we propose PolySeq, a fully de novo sequencing workflow that integrates bottom-up, top-down, and intact mass spectrometry data to accurately sequence pAb samples without relying on external databases. Our workflow automates the entire sequencing process from peptides to full proteins, achieving complete and accurate antibody profiles. Evaluation results on a mixture of four known mAbs and a pAb sample derived from mouse myeloma demonstrate that our de novo antibody sequences achieved up to 100% coverage and accuracy, with strong supporting evidence from bottom-up, top-down, and intact mass data. Furthermore, antibodies recombinantly expressed using de novo sequencing results showed expected properties, such as binding affinity and antigen neutralization, thus confirming the accuracy and efficacy of our pAb de novo sequencing workflow.

2025-10-31 | PXD063526 | Pride

A dataset describing a suite of novel antibody reagents for the RAS signaling network

Project description:RAS genes are frequently mutated in cancer and have for decades eluded effective therapeutic attack. The National Cancer Institute’s RAS Initiative has a focus on understanding pathways and discovering therapies for RAS-driven cancers. Part of these efforts is the generation of novel reagents to enable the quantification of RAS network proteins. Here we present a dataset describing the development, validation (following consensus principles developed by the broader research community), and distribution of 104 monoclonal antibodies (mAbs) enabling detection of 27 phosphopeptides and 69 unmodified peptides from 20 proteins in the RAS network. The dataset characterizes the utility of the antibodies in a variety of applications, including Western blotting, immunoprecipitation, protein array, immunohistochemistry, and targeted mass spectrometry. All antibodies and characterization data are publicly available through the CPTAC Antibody Portal, Panorama Public Repository, and/or PRIDE databases. These reagents will aid researchers in discerning pathways and measuring expression changes in the RAS signaling network.

2019-07-18 | PXD012130 | Pride

Mass spectrometric ITEM-TWO analyses of interactions between human cardiac Troponin T (hcTnT) peptides and the M7 or the M11.7 antiTnT antibodies.

Project description:Molecular characterization of antibodies M7, and M11.7, as well as the antiTNF alpha antibody in addition to the synthetic peptides P11-P17 and P21-P32. The M7 and M11.7 anti-human cardiac Troponin T (antihcTnT) antibodies from Roche Diagnostics Deutschland GmbH (Mannheim, Germany) and the antiTNF alpha antibody from Thermo Fisher Scientific (Waltham, MA, USA, cat.no. 28401) were reconstituted and diluted with 200 mM ammonium acetate, pH 6.7, for nano-electrospray mass spectrometry. Molecular masses were determined. Synthesized peptides P11-P17 and P21-P32, delivered by 'Peptide&Elephants' (Henningsdorf, Germany), were dissolved in 200 mM ammonium acetate, pH 6.7, and also forwarded to nano-electrospray mass spectrometric analysis. Molecular masses and amino acid sequences were determined by mass spectrometric fragmentation of precursor ions. ITEM TWO: The antibodies M7, M11.7 and antiTNF alpha were incubated with selected synthesized peptides to generate solutions which contained the antibody and one synthesized peptide, dissolved in 200 mM ammonium acetate, pH 6.7. Antibody – peptide solutions were subjected to nano electrospray mass spectrometric ITEM-TWO analyses to investigate the binding behavior of the antibody and synthesized peptides, such as the apparent binding energies and dissociation constants of the complex dissociation reactions in the gas phase.

2025-05-20 | PXD058812 | Pride

De Novo Sequencing of SARS-CoV-2 and influenza monoclonal antibodies by mass spectrometry using HCD and EThcD fragmentation and Supernovo software

Project description:In this study, we used electron-transfer/higher energy collision dissociation (EThcD) fragmentation to develop a mass-spectrometric (MS) method for distinguishing between Ile and Leu in Bovine Serum Albumin (BSA) and a SARS-CoV-1 anti-receptor binding domain (RBD) Spike monoclonal antibody (mAb). Supplemental activation normalized collision energy (SA-NCE) values were optimized. Combinations of multiple enzyme digestions, coupled with higher-energy collisional dissociation (HCD) and EThcD fragmentation, were used to increase coverage of all amino acid residues of the antibody. The data was searched with Supernovo™, which generated a complete de novo sequence for the test mAb and two additional SARS-CoV-2 human mAbs, giving correct sequences for the variable regions and selection between Ile and Leu residues. We then used the method on an additional set of twenty-five anti-hemagglutinin (HA) influenza antibodies of unknown sequence and determined high confidence sequences for >99% of the complementarity determining regions (CDRs). Importantly, the recombinant expression of these mAbs verified their binding and specificity to the HA influenza antigen. Unique glycosylation sites were also identified for eight antibodies. Our findings indicate this methodology results in almost complete antibody sequence coverage with >90% of residues determined with high confidence. Ile/Leu residues can be differentiated and glycosylation sites can be reliably identified.

2022-06-03 | PXD030094 | Pride

Human monoclonal antibodies to M. tuberculosis arabinomannan recognize distinct glycan epitopes - implications for TB diagnostics and research

Project description:Human antibody responses to AM/LAM are heterogenous and knowledge of reactivity to specific glycan epitopes at the monoclonal level is limited. Using novel glycan arrays, we characterized very high affinity monoclonal antibodies to AM/LAM, determined these mAbs are non-competing, and recognized distinct glycan epitopes. distinct from other anti-AM/LAM mAbs reported.

2021-07-21 | GSE180517 | GEO

Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies

Project description:Many human monoclonal antibodies that neutralize multiple clades of HIV-1 are polyreactive and bind avidly to mammalian autoantigens. Indeed, the generation of neutralizing antibodies to the 2F5 and 4E10 epitopes of HIV-1 gp41 in man may be proscribed by immune tolerance since mice expressing the VH and VL regions of 2F5 have a block in B-cell development characteristic of central tolerance. This developmental blockade implies the presence of tolerizing autoantigens that are mimicked by the membrane-proximal external region of HIV-1 gp41. Here we identify human kynureninase (KYNU) and splicing factor 3b subunit 3 (SF3B3) as the primary conserved, vertebrate self-antigens recognized by the 2F5 and 4E10 antibodies, respectively. 2F5 binds the H4 domain of KYNU which contains the complete 2F5 linear epitope (ELDKWA). 4E10 recognizes a conformational epitope of SF3B3 that is strongly dependent on hydrophobic interactions. Opossums carry a rare KYNU H4 domain that abolishes 2F5 binding, but retain all SF3B3 4E10 epitopes. Immunization of opossums with HIV-1 gp140 induced extraordinary titers of serum antibody to the 2F5 ELDKWA epitope but little or nothing to the 4E10 determinant. Identification of structural motif shared by vertebrates and HIV-1 provides direct evidence that immunological tolerance can impair humoral responses to HIV-1. The invitrogen protoarray that contains >9,400 recombinant human proteins was used to identify self-ligands that are recognized by broadly neutralizing HIV-1 antibodies 2F5 and 4E10. An isotype-matched human myeloma protein (151K, Southern Biotech) was used as control.

2012-12-03 | E-GEOD-42673 | biostudies-arrayexpress